Moli1901, a novel investigative compound for the treatment of cystic fibrosis (CF) is being developed by AOP Orphan Pharmaceuticals AG in Europe under a licensing and commercialization agreement with Lantibio, Inc.
The two companies have recently announced the positive final results of its Phase II clinical study of Moli1901, which was designed to investigate safety and tolerability of aerosolized Moli1901 in adolescents (12 years of age or older) and adults with CF.
Results of the study demonstrated that subjects ages 12 and older tolerated daily administration of Moli1901 over 28 days of daily dosing by the inhalation route and analysis of the data did not reveal unexpected safety concerns.
Notably, although the study was not powered to demonstrate efficacy, patients who received 2.5 mg Moli1901 per day demonstrated a statistically significant improvement of lung function as demonstrated by FEV1, a standard measure of lung capacity in CF patients.
Find more details from the press release.
[Photo Credit: nlm.nih.gov]
Comment Preview